IMMATICS BIOTECHNOLOGIES

immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severe side effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficie... ncy, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche.
IMMATICS BIOTECHNOLOGIES
Industry:
Biotechnology Medical Therapeutics
Founded:
2000-01-01
Address:
Tübingen, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.immatics.com
Total Employee:
51+
Status:
Active
Contact:
(707) 153-970
Total Funding:
446.23 M USD
Technology used in webpage:
IPv6 Strato Strato DNS
Similar Organizations
Advicenne
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare kidney diseases.
Aelis Farma
Aelis Farma is a biotech company conducting research and development on innovative signaling specific drugs
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Amunix
Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics.
arGEN-X
arGEN-X offers a platform for antibody lead choice that supports the discovery of human antibody therapeutics.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
BaroFold
BaroFold is a biopharmaceutical company focused on the development of protein therapeutics for immunology indications.
CellCentric
CellCentric is a biotechnology company that targets at deubiquitinase (DUB) enzyme for cancer therapy.
Cellmover
Cellmover specializes in the development of therapeutics for cancer immunotherapy.
Ciloa
Ciloa is a uniquely positioned to support your projects aiming to create new therapeutic.
Codiak Biosciences
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
Collegium Pharmaceutical
Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
CureVac
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.
DiaMedica
DiaMedica is a biopharmaceutical company focused on developing innovative treatments for stroke.
Enara Bio
Ervaxx is illuminating the immune interface to develop new cancer therapies.
Gadeta
Gadeta is a research and development company that develops immunotherapies for cancer.
IGM Biosciences
IGM Biosciences is a biotechnology company pioneering the development of engineered IgM antibodies.
Precigen
Precigen is a life sciences company researching and developing bio-therapeutic control systems to minimize toxicity.
Liquidia Technologies
Liquidia Technologies is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics.
MabVax Therapeutics
MabVax is a biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies.
MiReven
MiReven is a biopharmaceutical company focused on developing miR-7 as a cancer therapy.
NexImmune
NexImmune is a biopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology.
NFlection Therapeutics
NFlection focuses on the development of novel therapies to address the needs of patients.
NuCana BioMed
NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.
OccuRx
OccuRx is a biopharmaceutical company that focuses on the development of innovative therapeutic strategies.
Oncology Pharma
Oncology Pharma is engages in research and development of therapeutics for oncology.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Rhovac ApS
RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells.
Sensorion
Sensorion is a France-based biopharmaceutical company developing targeted therapeutic solutions for the treatment of vestibular deficits.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
SpringWorks Therapeutics
SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.
Telomium
Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy.
Theranexus
Theranexus is a clinical-stage pharmaceutical company that aims to develop technology to address severe medical needs in brain disorders.
UmanDiagnostics
UmanDiagnostics supplies neurofilament light (Nf-L) antibodies and ELISA kits to advance the development of therapeutics and diagnostics.
Current Advisors List
Board_member
Board_member
2012-11-01
Board_member
Advisor
Board_member
Advisor
Advisor
Advisor
Current Employees Featured
Carolin Mauch Associate Director Financial Planning & Analysis @ immatics biotechnologies
Associate Director Financial Planning & Analysis
Martin Hofmann Associate Director Immunology @ immatics biotechnologies
Associate Director Immunology
2019-07-01
Norbert Hilf VP Translational Development @ immatics biotechnologies
VP Translational Development
2018-01-01
Martina Ott Associate Director Target Validation @ immatics biotechnologies
Associate Director Target Validation
Arun Satelli Associate Director @ immatics biotechnologies
Associate Director
2017-12-01
Steffen Walter Chief Technology Officer @ immatics biotechnologies
Chief Technology Officer
2020-06-01
Arnd Christ Chief Financial Officer @ immatics biotechnologies
Chief Financial Officer
2020-10-01
Toni Weinschenk CTO @ immatics biotechnologies
CTO
2017-09-01
Sonja Dorner Associate Director @ immatics biotechnologies
Associate Director
2019-01-01
Frank Schwöbel Associate Director Preclinical Pharmacology & Pharmacokinetics @ immatics biotechnologies
Associate Director Preclinical Pharmacology & Pharmacokinetics
2017-10-01
Founder
Stock Details
Investors List
AT Impf
AT Impf investment in Post-IPO Equity - immatics biotechnologies
dievini Hopp Biotech Holding
dievini Hopp Biotech Holding investment in Post-IPO Equity - immatics biotechnologies
Redmile Group
Redmile Group investment in Post-IPO Equity - immatics biotechnologies
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - immatics biotechnologies
Wellington Partners
Wellington Partners investment in Post-IPO Equity - immatics biotechnologies
Sphera Funds Management
Sphera Funds Management investment in Post-IPO Equity - immatics biotechnologies
RTW Investments LLC
RTW Investments LLC investment in Post-IPO Equity - immatics biotechnologies
Celgene
Celgene investment in Venture Round - immatics biotechnologies
Wellington Partners
Wellington Partners investment in Series E - immatics biotechnologies
dievini Hopp Biotech Holding
dievini Hopp Biotech Holding investment in Series E - immatics biotechnologies
Official Site Inspections
http://www.immatics.com Semrush global rank: 2.22 M Semrush visits lastest month: 8.71 K
- Host name: ds187313.goserver.host
- IP address: 185.30.33.118
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin

More informations about "immatics biotechnologies"
immatics biotechnologies - Crunchbase Company …
Organization. immatics biotechnologies . Connect to CRM . Save . Summary. …See details»
Immatics Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Immatics has 5 employees across 4 locations and €155.84 m in annual revenue in FY 2024. See insights on Immatics including office locations, competitors, revenue, financials, …See details»
Immatics - LinkedIn
Immatics | 25,896 followers on LinkedIn. Delivering the Power of T Cells to Patients with Cancer | Immatics combines the discovery of true targets for …See details»
Immatics - pharmaceutical Technology
Immatics’ approach towards the goal of opening new avenues of treatment for cancer patients starts with the discovery and validation of true targets (using the XPRESIDENT ® platform). In …See details»
immatics - VentureRadar
" immatics biotechnologies GmbH, founded 2000 at Tubingen's Department of Immunology, capitalizes on groundbreaking discoveries investigating the role of tumor-associated peptides …See details»
Immatics - Overview, News & Similar companies | ZoomInfo.com
Nov 14, 2023 Immatics Announces Third Quarter 2023 Financial Results and Business Update Tuebingen, Germany and Houston, TX, November 14, 2023 – Immatics N.V. (NASDAQ: …See details»
Locations - Immatics
Immatics operates as a transatlantic organization with the team spanning from Tübingen and Munich, Germany to Houston, Texas. The long-term integration of the European and US sites …See details»
Locations – Immatics
Immatics operates as a transatlantic organization with the team spanning from Tübingen and Munich, Germany to Houston, Texas. The long-term integration of the European and US sites …See details»
Immatics: Revenue, Worth, Valuation & Competitors 2025
Immatics has an estimated revenue of $111M, and 552 employees. Alternatives of Immatics are Imaging Endpoints, Southern Scripts and Alfasigma USA. ... Organization Immatics …See details»
Investors & Media | Immatics N.V.
Immatics Biotechnologies GmbH Paul-Ehrlich-Str. 15 72076 Tuebingen Germany. Phone: +49 7071 5397-0 Fax: +49 7071 5397-900 E-Mail: info@immatics.com. Immatics US, Inc. 13203 …See details»
Immatics NV - Drug pipelines, Patents, Clinical trials - Synapse
BMS and Immatics started working together in 2019, when the pharma company spent $75 million upfront on options for three of the biotech’s T cell receptor therapy targets. Two years later, …See details»
About - Immatics
In 2015, Immatics and MD Anderson Cancer Center launched Immatics US, Inc. in Houston, Texas as a joint venture to develop transformative Adoptive Cell Therapies. Immatics N.V. …See details»
About – Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors to enable a robust and specific T cell response …See details»
Jobs - Immatics
Immatics N.V. Immatics Biotechnologies GmbH Paul-Ehrlich-Str. 15 – 19 72076 Tuebingen Germany. Phone: +49 7071 5397-0 Fax: +49 7071 5397-900 E-Mail: info@immatics.com. …See details»
Technologies – Immatics
Immatics’ approach to opening new avenues of treatment for cancer patients starts with the discovery and validation of true targets using the XPRESIDENT ® platform. XPRESIDENT ® …See details»
Careers - Immatics
Fundamentally, Immatics is its employees: Like every organization, our corporate culture is wholly defined by the team and the systems set in place to facilitate an innovative, collaborative, …See details»
Pipeline - Immatics
In these partnerships, Immatics seeks to evaluate and develop programs based on novel Immatics-derived targets in a variety of immunotherapeutic approaches. From its research and …See details»
Immatics – Delivering the power of T cells to cancer patients
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell …See details»
immatics n.v. announces upcoming annual general meeting
1 day ago The company, previously known as Immatics B.V., changed its name in April 2020. The filing, submitted under Form 6-K, is part of the company’s compliance with the Securities …See details»
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 …
4 days ago Stafford, Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the …See details»